AI Tool Comparison
Comparing as AI Medical Research & Clinical Decision SupportSchrödinger vs Recursion Pharmaceuticals
Schrödinger
VS
Recursion Pharmaceuticals
Verdict by Category
Detailed category analysis is not available for this comparison.
Detailed Comparison
Feature
Schrödinger
Recursion Pharmaceuticals
Pricing
PaidSchrödinger offers software through subscription licenses and hosted cloud access.
Enterprise pharma customers access the full suite (Maestro, Glide, FEP+, Jaguar, Prime, and Bunsen AI) through annual software licensing agreements. Pricing is tiered by organization size, usage volume, and modules required. Enterprise software ACV reached $198.5M in 2025.
Academic and government institutions access Schrödinger tools through educational licensing at significantly reduced rates. Cloud-hosted subscriptions are also available for teams preferring managed infrastructure.
Drug discovery partnerships with pharma (BMS, Sanofi, Takeda) are structured as sponsored research and co-development agreements with milestone-based payments. Contact Schrödinger through schrodinger.com for enterprise pricing, academic licenses, or partnership inquiries.
CustomRecursion operates through three revenue streams: pharma collaboration agreements, data licensing, and its own internal drug pipeline.
Pharma partnerships (Roche/Genentech, Sanofi) are structured as multi-year agreements with upfront payments and milestone-based payments tied to program progress. Recursion has earned $500M+ in cumulative milestones to date, with $134M from Sanofi alone.
Data licensing allows external researchers and pharma companies to access Recursion's proprietary biology maps and phenomics datasets for their own target discovery programs.
Recursion's own clinical programs (REC-4881, REC-1245, REC-4539) will generate revenue through future partnering, co-development, or commercialization deals as they advance through clinical trials. Total 2025 revenue: $74.7M. Contact Recursion through recursion.com for partnership inquiries.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Summary
Physics-based drug discovery with Bunsen AI co-scientist — trusted by 500+ pharma companies worldwide
AI-native drug discovery OS with industrial-scale automated labs and $500M+ in pharma partnerships
Schrödinger Pros & Cons
Pros
- 34+ years of computational chemistry leadership — most trusted physics-based platform in pharma
- Bunsen AI co-scientist launched July 2026 — BMS immediately deployed it
- FEP+ delivers industry-leading accuracy in binding affinity prediction
- NASDAQ SDGR — $255.87M revenue in 2025, 23% growth, turning profitable in Q2 2026
- 500+ pharma enterprise customers including BMS, Sanofi, Takeda, Pfizer, and Eli Lilly
- Materials science applications extend reach to battery, semiconductor, and chemical sectors
- Cloud-hosted subscriptions eliminate on-premise infrastructure burden
Cons
- Software is expensive — enterprise pricing puts it out of reach for smaller labs
- Stock (SDGR) has been under pressure — market cap ~$1B despite strong platform
- Drug discovery segment revenue is milestone-dependent and lumpy
- Platform learning curve is steep without computational chemistry background
- Competition from newer, purely AI-native platforms is intensifying
Recursion Pharmaceuticals Pros & Cons
Pros
- $500M+ in pharma partnership milestones — most validated AI drug platform by commercial revenue
- Recursion OS is the most vertically integrated AI drug discovery system — biology to clinic in one platform
- Industrial-scale automated labs generate data no other company can replicate
- Phase 2 FAP clinical proof of concept — 53% polyp reduction — FDA registration discussions began
- Roche/Genentech and Sanofi as partners — two of the world's top 5 pharma companies
- Exscientia acquisition in 2024 added cutting-edge small molecule AI design capabilities
- Cash runway guided into early 2028 — disciplined capital allocation
Cons
- Stock (RXRX) is below $5 — significant market skepticism on timeline to commercial drugs
- Operating cash burn of ~$390M in 2026 — needs continued capital or milestone payments
- Acquired Exscientia in 2024 — integration complexity and added operational overhead
- No approved drugs yet — clinical proof of concept still early stage
- Proprietary platform requires industrial-scale automation infrastructure that can't be self-built